Exelixis, Inc. (EXEL)

Exelixis, Inc. is a biotechnology company founded in 1994, specializing in the development of cancer treatments. Headquartered in Alameda, California, Exelixis focuses on discovering and developing novel therapies to improve the lives of cancer patients. The company is well-known for its flagship product, Cabometyx (cabozantinib), which is used to treat certain types of kidney and liver cancers. As of my knowledge cutoff in October 2023, Michael M. Morrissey serves as the President and CEO. Exelixis is committed to advancing its robust pipeline through innovative research in oncology, striving to make a significant impact on cancer care. The company's dedication to addressing unmet medical needs has driven its growth, leading to a reported revenue of over $1 billion annually in recent years.